Novo Nordisk A/S News - October 10, 2026

Novo Nordisk's Patent Wall Is Crumbling — Can Its Pipeline Outrun the Generic Tide?

Shares of Novo Nordisk edged up 0.2% to $254.30 on Oct. 10, a muted reaction to a potentially seismic development: the European Patent Office's Board of...

Novo Nordisk Loses Patent, Threatening Ozempic and Wegovy Exclusivity From 2031

The European Patent Office’s (EPO) Board of Appeal revoked Novo Nordisk’s patent EP 3 448 416, which covered its semaglutide products Wegovy and Ozempic. The...